Lecicarbon Pediatrickí Pacienti

Sodium hydrogen carbonate and sodium dihydrogen phosphate, the active ingredients in Lecicarbon Pediatrickí Pacienti, are buffering agents presented as an unspecified strength and rectal formulation for pediatric use. They help correct gastrointestinal acid‑base disturbances in children requiring rectal administration by supplying bicarbonate and phosphate ions that neutralize excess acidity and support normal pH balance.

GNH USA supplies Lecicarbon Pediatrickí Pacienti as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lecicarbon Pediatrickí provides rectal buffering for pediatric patients with conditions affecting acid‑base balance. - Metabolic acidosis (gastrointestinal): restores normal gastric pH and reduces acidity. - Renal tubular acidosis (pediatric): supplies bicarbonate to counteract systemic acid load. - Diarrhea‑associated acidosis: buffers excess intestinal acid to improve comfort and electrolyte stability.

Lecicarbon Pediatrickí may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Rectal irritation or mild burning sensation. - Abdominal discomfort or cramping. - Nausea or mild vomiting. - Flatulence or transient diarrhea. - Mild electrolyte imbalance (e.g., slight sodium shift). - Transient headache.

Serious or Rare Side Effects: - Severe electrolyte disturbances such as hypernatremia or hypophosphatemia. - Severe abdominal pain or colitis. - Allergic reactions including rash, itching, or anaphylaxis. - Persistent vomiting or dehydration. - Acute renal impairment in susceptible patients.

When prescribing Lecicarbon Pediatrickí, consider the following precautions: - Age restriction: use only in pediatric patients as directed by a healthcare professional. - Renal impairment: monitor renal function and electrolyte levels closely. - Electrolyte disorders: avoid in patients with existing hypernatremia or severe phosphate imbalance. - Concurrent acidifying agents: use with caution as they may reduce buffering efficacy. - Pregnancy and lactation: safety not established; use only if potential benefit justifies the risk. - Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lecicarbon Pediatrickí can interact with other medications that affect acid‑base balance or electrolyte status.

Major Interactions (Avoid): - Strong acidifying agents (e.g., ammonium chloride): may negate buffering effect. - Intravenous sodium bicarbonate: risk of excessive alkalinization. - High‑dose phosphate binders: may cause phosphate overload.

Moderate Interactions (Monitor Closely): - Diuretics (e.g., furosemide): may alter sodium and potassium balance. - ACE inhibitors or ARBs: monitor for changes in potassium levels. - Antacids containing aluminum or magnesium: may affect absorption of the buffering agents.